5.16
Schlusskurs vom Vortag:
$5.01
Offen:
$4.97
24-Stunden-Volumen:
387.85K
Relative Volume:
0.44
Marktkapitalisierung:
$353.05M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-96.66M
KGV:
-2.40
EPS:
-2.15
Netto-Cashflow:
$-83.73M
1W Leistung:
+10.02%
1M Leistung:
+4.03%
6M Leistung:
-41.23%
1J Leistung:
-43.97%
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Firmenname
Olema Pharmaceuticals Inc
Sektor
Branche
Telefon
(415) 651-3316
Adresse
780 BRANNAN STREET, SAN FRANCISCO
Vergleichen Sie OLMA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
OLMA
Olema Pharmaceuticals Inc
|
5.16 | 320.90M | 0 | -96.66M | -83.73M | -2.15 |
![]()
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-04-02 | Eingeleitet | Goldman | Buy |
2024-01-30 | Eingeleitet | Citigroup | Buy |
2023-07-21 | Eingeleitet | Oppenheimer | Outperform |
2023-05-05 | Eingeleitet | CapitalOne | Overweight |
2023-02-22 | Eingeleitet | Credit Suisse | Outperform |
2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
2022-06-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2022-02-28 | Eingeleitet | H.C. Wainwright | Neutral |
2021-12-07 | Fortgesetzt | Cowen | Outperform |
2020-12-14 | Eingeleitet | Canaccord Genuity | Buy |
2020-12-14 | Eingeleitet | Cowen | Outperform |
2020-12-14 | Eingeleitet | JP Morgan | Overweight |
2020-12-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High? - MSN
Olema Oncology Advances Cancer Trials with Strong Financials - TipRanks
Olema Oncology to Participate in Upcoming Investor Conferences | - GuruFocus
Olema Oncology to Participate in Upcoming Investor Conferences | OLMA Stock News - GuruFocus
Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire
Breast Cancer Biotech Olema Sets Major Presentations at Goldman Sachs and Jefferies Healthcare Conferences - Stock Titan
BNP Paribas Financial Markets Makes New $1.13 Million Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Paradigm Biocapital Advisors LP Purchases 1,801,370 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Price T Rowe Associates Inc. MD Has $153,000 Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
MPM Bioimpact LLC Acquires 231,954 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
The Goldman Sachs Group Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $18.00 - Defense World
Oppenheimer Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $22.00 - Defense World
Q2 EPS Estimate for Olema Pharmaceuticals Raised by Analyst - Defense World
Voya Investment Management LLC Cuts Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Driehaus Capital Management LLC Takes $1.28 Million Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth - Yahoo Finance
Olema Pharmaceuticals (OLMA) Price Target Lowered by Oppenheimer - GuruFocus
Balyasny Asset Management L.P. Increases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals (OLMA) Price Target Lowered by Goldman Sachs | OLMA Stock News - GuruFocus
Olema Oncology (OLMA) Price Target Adjusted Amid Upcoming Data R - GuruFocus
Lightspeed Management Company L.L.C. Makes New Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Oncology (OLMA) Pushes Forward with Promising Cancer Treat - GuruFocus
Olema Oncology (OLMA) Pushes Forward with Promising Cancer Treatments | OLMA Stock News - GuruFocus
Olema Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Olema Oncology Reports First Quarter 2025 Financial and Operating Results - The Manila Times
Olema Oncology Strengthens Breast Cancer Pipeline: Key Phase 3 Trial Updates and $392M War Chest - Stock Titan
Hsbc Holdings PLC Invests $58,000 in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals (OLMA) Projected to Post Earnings on Wednesday - MarketBeat
Deep Track Capital LP Decreases Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Dimensional Fund Advisors LP Cuts Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Wells Fargo & Company MN Raises Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by BVF Inc. IL - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Barclays PLC - Defense World
Boxer Capital Management LLC Takes Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Market Insight: Olema Pharmaceuticals Inc (OLMA)’s Notable Drop, Closing at 4.60 - DWinneX
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Acquired by Renaissance Technologies LLC - MarketBeat
HC Wainwright Reaffirms Buy Rating for Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | OLMA Stock News - GuruFocus
Finanzdaten der Olema Pharmaceuticals Inc-Aktie (OLMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):